We are advising AnHeart Therapeutics on the acquisition

Davis Polk is advising AnHeart Therapeutics Ltd. on its all-stock acquisition by Nuvation Bio Inc. The transaction is subject to approval by AnHeart’s shareholders and other customary closing conditions and is expected to close in the second quarter of 2024.

AnHeart Therapeutics is a clinical-stage biopharmaceutical company developing novel precision therapies for people with cancer. AnHeart’s lead investigational therapy, taletrectinib, is a next-generation ROS1-inhibitor currently in pivotal Phase 2 trials for ROS1-positive non-small cell lung cancer. AnHeart’s second investigational therapy, safusidenib, is a mIDH1-inhibitor being evaluated in a Phase 2 trial for IDH1-mutant glioma. Anheart was founded in 2018 and is headquartered in New York City and China.

Nuvation Bio is a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates. Nuvation Bio’s proprietary portfolio includes mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. Nuvation Bio was founded in 2018 by biopharma industry veteran David Hung, M.D., and is headquartered in San Francisco, California. 

The Davis Polk corporate team includes partners Lee Hochbaum and Yasin Keshvargar and associates Neil Bhatt, Steven Jaffe and Chase Belford. Partner Kara L. Mungovan and associate Danielle Rapaccioli are providing tax advice. Partner Travis Triano and associate Laetitia Krisel are providing executive compensation advice. Partner David R. Bauer is providing intellectual property advice. All members of the Davis Polk team are based in the New York office.

Copy link to share post